Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Assets: 2019-2024

Historic Assets for Allogene Therapeutics (ALLO) over the last 6 years, with Dec 2024 value amounting to $548.7 million.

  • Allogene Therapeutics' Assets fell 25.35% to $439.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $439.8 million, marking a year-over-year decrease of 25.35%. This contributed to the annual value of $548.7 million for FY2024, which is 14.64% down from last year.
  • Per Allogene Therapeutics' latest filing, its Assets stood at $548.7 million for FY2024, which was down 14.64% from $642.8 million recorded in FY2023.
  • Allogene Therapeutics' Assets' 5-year high stood at $1.2 billion during FY2020, with a 5-year trough of $548.7 million in FY2024.
  • Moreover, its 3-year median value for Assets was $642.8 million (2023), whereas its average is $671.0 million.
  • Per our database at Business Quant, Allogene Therapeutics' Assets soared by 71.05% in 2020 and then dropped by 21.82% in 2022.
  • Allogene Therapeutics' Assets (Yearly) stood at $1.2 billion in 2020, then fell by 14.42% to $1.1 billion in 2021, then dropped by 21.82% to $821.6 million in 2022, then fell by 21.76% to $642.8 million in 2023, then declined by 14.64% to $548.7 million in 2024.